Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | What are the differences in health technology assessment (HTA) across Europe?

Jean-Luc Harousseau • 28 Mar 2017
EBMT 2017

Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France, discusses the differences in the evaluation of value of new agents across Europe at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. He explains that some health technology assessments (HTA) are based on clinical evaluation alone, while other assessments are based on health economic evaluation. Prof. Harousseau points out the differences in assessments between different countries, and concludes that this makes harmonization of health technology assessment evaluations across Europe a challenge.

More from Jean-Luc Harousseau

4:33
Making sense of the many treatment options for relapsed MM: cost-effectiveness
Jean-Luc Harousseau • 19 Apr 2018
3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau • 28 Mar 2017
6:17
Why novel multiple myeloma drugs are expensive
Jean-Luc Harousseau • 29 Apr 2016
1:43
Why patients should be involved in evaluating novel drugs in multiple myeloma
Jean-Luc Harousseau • 23 Apr 2016
The content of VJHemOnc is intended for healthcare professionals